Update on statin therapyBALLANTYNE, Christie M.Cardiovascular reviews & reports. 2002, Vol 23, Num 1, pp 60-61, issn 0197-3118Article

A symposium: management summit on improving practice outcomeBALLANTYNE, Christie M.The American journal of cardiology. 2000, Vol 85, Num 3A, issn 0002-9149, 59 p.Conference Proceedings

Role of biomarkers in developing new therapies for vascular diseaseNAMBI, Vijay; BALLANTYNE, Christie M.World journal of surgery. 2007, Vol 31, Num 4, pp 676-681, issn 0364-2313, 6 p.Conference Paper

Combination therapy with statins and omega-3 fatty acidsNAMBI, Vijay; BALLANTYNE, Christie M.The American journal of cardiology. 2006, Vol 98, Num 4, issn 0002-9149, 34i-38i, SUPArticle

Role of lipid and lipoprotein profiles in risk assessment and therapyBALLANTYNE, Christie M; HOOGEVEEN, Ron C.The American heart journal. 2003, Vol 146, Num 2, pp 227-233, issn 0002-8703, 7 p.Article

Niacin Therapy: An Evolving Paradigm for the Management of Mixed Dyslipidemia and Low High-Density Lipoprotein CholesterolDAVIDSON, Michael H; BALLANTYNE, Christie M.The American journal of cardiology. 2008, Vol 101, Num 8A, issn 0002-9149, 64 p., SUPSerial Issue

Rationale and design of the Cardiac Hospitalization Atherosclerosis Management program at the University of California Los AngelesFONAROW, G. C; GAWLINSKI, A.The American journal of cardiology. 2000, Vol 85, Num 3A, pp 10A-17A, issn 0002-9149Conference Paper

Conditional risk factors for atherosclerosisKULLO, Iftikhar J; BALLANTYNE, Christie M.Mayo Clinic proceedings. 2005, Vol 80, Num 2, pp 219-230, issn 0025-6196, 12 p.Article

Fluvastatin: Clinical and safety profileCORSINI, Alberto; JACOBSON, Terry A; BALLANTYNE, Christie M et al.Drugs (Basel). 2004, Vol 64, Num 12, pp 1305-1323, issn 0012-6667, 19 p.Article

Achieving greater reductions in cardiovascular risk: Lessons from statin therapy on risk measures and risk reductionBALLANTYNE, Christie M.The American heart journal. 2004, Vol 148, Num 1, pp 3-8, issn 0002-8703, 6 p., SUPConference Paper

Safety of Niacin and Simvastatin Combination TherapyBAYS, Harold.The American journal of cardiology. 2008, Vol 101, Num 8A, issn 0002-9149, 3B-8B, SUPArticle

Rationale for targeting multiple lipid pathways for optimal cardiovascular risk reductionBALLANTYNE, Christie M.The American journal of cardiology. 2005, Vol 96, Num 9A, pp 14K-19K, issn 0002-9149, SUPConference Paper

Efficacy and safety of an extended-release formulation of fluvastatin for once-daily treatment of primary hypercholesterolemiaBALLANTYNE, Christie M; MCKENNEY, James; TRIPPE, Bruce S et al.The American journal of cardiology. 2000, Vol 86, Num 7, pp 759-763, issn 0002-9149Article

Management of metabolic syndrome: statinsXYDAKIS, Antonios M; BALLANTYNE, Christie M.Endocrinology and metabolism clinics of North America. 2004, Vol 33, Num 3, issn 0889-8529, vi, 509-523 [16 p.]Article

Combination therapy for combined dyslipidemiaXYDAKIS, Antonios M; BALLANTYNE, Christie M.The American journal of cardiology. 2002, Vol 90, Num 10B, pp 21K-29K, issn 0002-9149Conference Paper

Evidence to Support Aggressive Management of High-Density Lipoprotein Cholesterol : Implications of Recent Imaging TrialsTAYLOR, Alien J.The American journal of cardiology. 2008, Vol 101, Num 8A, issn 0002-9149, 36B-43B, SUPArticle

Point high-sensitivity C-reactive protein and cardiac C-reactive protein assays : Is there a need to differentiate?RIFAI, Nader; BALLANTYNE, Christie M; CUSHMAN, Mary et al.Clinical chemistry (Baltimore, Md.). 2006, Vol 52, Num 7, pp 1254-1257, issn 0009-9147, 4 p.Article

Effects of SREBF-1a and SCAP polymorphisms on plasma levels of lipids, severity, progression and regression of coronary atherosclerosis and response to therapy with fluvastatinSALEK, Lorraine; LUTUCUTA, Silvia; BALLANTYNE, Christie M et al.Journal of molecular medicine (Berlin. Print). 2002, Vol 80, Num 11, pp 737-744, issn 0946-2716, 8 p.Article

Strategies for implementing lipid-lowering therapy : Pharmacy-based approachBIRTCHER, K. K; BOWDEN, C; BALLANTYNE, C. M et al.The American journal of cardiology. 2000, Vol 85, Num 3A, pp 30A-35A, issn 0002-9149Conference Paper

Low-density lipoprotein and high-density lipoprotein cholesterol levels in relation to genetic polymorphisms and menopausal status : The Atherosclerosis Risk in Communities (ARIC) StudyCHAMBERLAIN, Alanna M; FOLSOM, Aaron R; SCHREINER, Pamela J et al.Atherosclerosis. 2008, Vol 200, Num 2, pp 322-328, issn 0021-9150, 7 p.Article

Mechanism of Action of NiacinKAMANNA, Vaijinath S; KASHYAP, Moti L.The American journal of cardiology. 2008, Vol 101, Num 8A, issn 0002-9149, 20B-26B, SUPArticle

Nicotinic Acid, Alone and in Combinations, for Reduction of Cardiovascular RiskBROWN, B. Greg; ZHAO, Xue-Qiao.The American journal of cardiology. 2008, Vol 101, Num 8A, issn 0002-9149, 58B-62B, SUPArticle

Interaction effects of high-density lipoprotein metabolism gene variation and alcohol consumption on coronary heart disease risk: The Atherosclerosis Risk in Communities StudyVOLCIK, Kelly; BALLANTYNE, Christie M; POWNALL, Henry J et al.Journal of studies on alcohol and drugs. 2007, Vol 68, Num 4, pp 485-492, issn 1937-1888, 8 p.Article

Statin Therapy Alters the Relationship Between Apolipoprotein B and Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol Targets in High-Risk Patients : The MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY II) Trial. CommentaryBALLANTYNE, Christie M; RAICHLEN, Joel S; CAIN, Valerie A et al.Journal of the American College of Cardiology. 2008, Vol 52, Num 8, pp 626-635, issn 0735-1097, 10 p.Article

Fluvastatin reduces cardiac mortality in patients with coronary heart diseaseBALLANTYNE, Christie M; RIEGGER, Günter; MOORE, Nicholas et al.Cardiovascular drugs and therapy. 2004, Vol 18, Num 1, pp 67-75, issn 0920-3206, 9 p.Article